Blood donation, deferral, and discrimination: FDA donor deferral policy for men who have sex with men

American Journal of Bioethics

Volumn 10, Issue 2, 2010, Pages 29-39

  Galarneau, Charlene ^a  

^a WELLESLEY COLLEGE   (United States)

Author keywords

Blood donors; Discrimination; Ethics; FDA; Sexual partners; Social justice

Indexed keywords

ARTICLE; BLOOD DONOR; DISEASE TRANSMISSION; DONOR SELECTION; ETHICS; FOOD AND DRUG ADMINISTRATION; HAITI; HEALTH CARE POLICY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEGAL ASPECT; MALE; RISK ASSESSMENT; RISK FACTOR; SAFETY; SEXUAL BEHAVIOR; SEXUALITY; SOCIAL JUSTICE; SOCIAL PSYCHOLOGY; STANDARD; TIME; UNITED STATES;

BLOOD DONORS; DONOR SELECTION; ETHICAL ANALYSIS; HAITI; HEALTH POLICY; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; PREJUDICE; RISK ASSESSMENT; RISK FACTORS; SAFETY; SEXUAL BEHAVIOR; SEXUAL PARTNERS; SOCIAL JUSTICE; TIME FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 76049088351     PISSN: 15265161     EISSN: 15360075     Source Type: Journal    
DOI: 10.1080/15265160903487619     Document Type: Article

References (62)

1. AABB. 2008. FDA liaison meeting, 3/11/08. Available at http://www.aabb.org/Content/MeetingsandEvents/GovernmentAdvisoryMeetings/FDALiaisonMeetings/flm031108.htm.
2. Advisory Committee on Blood Safety and Availability. 2000. Blood safety summary-August 2000. Available at http://www.hhs.gov/ophs/bloodsafety/summaries/sumaug00. html.
3. Bayer, R. 1999. Blood and AIDS in America: Science, politics, and the making of an iatrogenic catastrophe. In Blood feuds: AIDS, blood, and the politics of medical disaster, ed. R. Bayer and E. A. Feldman, 20-58. New York: Oxford University Press.
4. Blood Products Advisory Committee. 1990. Transcript of April 20 Meeting. Print copy obtained by author through Freedom of Information Act request.
5. Blood Products Advisory Committee. 1992. Transcript of March 13 meeting. Print copy obtained by author through Freedom of Information Act request.
6. Blood Products Advisory Committee. 1997. Transcript of December 11 meeting. Available at http://www.fda.gov/ohrms/dockets/ac/97/transcpt/3361t1.pdf.
7. Blood Products Advisory Committee. 2000. Transcript of September 14 meeting. Available at http://www.fda.gov/ohrms/dockets/ac/cber00.htm#Blood%20Products.
8. Blood Products Advisory Committee. 2008a. Blood Products Advisory Committee, Charter. June 9. Available at http://www.fda.gov/cber/advisory/bp/bpchart.htm.
9. Blood Products Advisory Committee. 2008b. Blood Products Advisory Committee, Committee Roster. December 31. Available at http://www.fda.gov/cber/advisory/bp/bpmembers.htm (accessed April 22, 2009).
10. Brooks, J. P. 2004. The rights of blood recipients should supersede any asserted rights of blood donors. Vox Sanguinis 87: 280-286.
11. Busch, M. P., S. A. Glynn, S. L. Stramer, D. M. Strong, S. Caglioti, D. J. Wright, B. Pappalardo, and S. H. Kleinman. 2005. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 45: 254-264.
12. Centers for Disease Control. 1982. Opportunistic infections and Kaposi's sarcoma among Haitians in the United States. Morbidity and Mortality Weekly Report 31(26): 353-354, 360-361.
13. Centers for Disease Control. 1983. Current trends prevention of acquired immune deficiency syndrome (AIDS): Report of inter-agency recommendations. Morbidity and Mortality Weekly Report 32(8): 101-103.
14. Centers for Disease Control. 1985. Current trends update: Acquired immunodeficiency syndrome-United States. Morbidity and Mortality Weekly Report. 34(18): 245-248.
15. Churchill, L. R. 2002. What ethics can contribute to health policy. In Ethical dimensions of health policy, ed. M. Danis, C. Clancy, and L. R. Churchill, 51-64. New York: Oxford University Press.
16. Cineas, F. N. 1983. Haitian ambassador deplores AIDS connection. New England Journal of Medicine 309(11): 668-669.
17. Culhane, J. G. 2005. Bad science, worse policy: The exclusion of gay males from donor pools. Saint Louis University Public Law Review 24: 129-149.
18. Department of Health and Human Services. 2006. The 2005 nationwide blood collection and utilization survey report. Washington, DC: DHHS.
19. Department of Health and Human Services. 2008. The 2007 nationwide blood collection and utilization survey report. Washington, DC: DHHS.
20. Farmer, P. 1992. AIDS and accusation: Haiti and the geography of blame. Berkeley: University of California Press.
21. Food and Drug Administration. 1983. Recommendations to decrease the risk of transmitting acquired immune deficiency syndrome (AIDS) from blood donors. In HIV and the blood supply: An analysis of crisis decisionmaking, ed. Institute of Medicine, 290-291. Washington, DC: National Academy Press.
22. Food and Drug Administration. 1992. Revised recommendations for the prevention of human immunodeficiency virus (HIV) transmission by blood and blood products. Available at http://www.fda.gov/cber/bldmem/hiv042392.pdf (accessed April 13, 2009).
23. Food and Drug Administration. 1998. Blood Donor Suitability Workshop, November 23. Available at http://www.fda.gov/cber/minutes/bld112398trans.htm.
24. Food and Drug Administration. 2002. FDA approves first nucleic acid test (NAT) system to screen whole blood donors for infections with human immunodeficiency virus (HIV) and hepatitis C virus (HCV). FDA Talk Paper, February 28. Available at http://www.aidsinfo.nih.gov/aprs/release.aspx?an=A00596§ion=default.
25. Food and Drug Administration. 2006. FDA workshop on behavior-based blood donor deferrals in the NAT era. Transcript, March 8 meeting. Available at http://www.fda.gov/cber/minutes/nat030806t.htm.
26. Food and Drug Administration. 2007a. FDA policy on blood donations from men who have sex with other men. Available at www.fda.gov/cber/faq/msmdonor.htm (accessed April 22,2009).
27. Food and Drug Administration. 2007b. FDA science and mission at risk: Report of the Subcommittee on Science and Technology. Available at http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4329b0201FDA%20Report%20on%20Science%20and%20Technologypdf.
28. Food and Drug Administration. 2009. About CBER. Available at http://www.fda.gov/cber/about.htm.
29. Food and Drug Administration. n.d. Overview and general information on advisory committee membership. Available at http://www.fda.gov/oc/advisory/vacancies/acvacfaq.html.
30. Franklin, I. M. 2007. Is there a right to donate blood? Patient rights; Donor responsibilities. Transfusion Medicine 17:161-168.
31. General Accounting Office. 2002. Blood supply generally adequate despite new donor restrictions, 1-36. Washington, DC: GAO.
32. Germain, M., R. S. Remis, and G. Delage. 2003. The risks and benefits of accepting men who have had sex with men as blood donors. Transfusion 43: 25-33.
33. Hilts, P. J. 1990. U.S. to alter screening of those giving blood. New York Times, December 5: A24.
34. Hochberg, F. A. 2002. HIV/AIDS and blood donation policies: A comparative study of public health policies and individual rights norms. Duke Journal of Comparative & International Law 12: 231-280.
35. Human Rights Campaign. 2009. Blood donations. Available at www.hrc.org/issues/4057.htm.
36. Institute of Medicine. 1995. HIV and the blood supply: An analysis of crisis decisionmaking. Washington, DC: National Academy Press.
37. Institute of Medicine. 1996. Blood banking and regulation: Procedures, problems, and alternatives. Washington, DC: National Academy Press.
38. Joint Statement: AABB, America's Blood Centers, and American Red Cross. 2006. Behavior-based blood donors in the era of nucleic acid testing (NAT). March 9. Available at http://www.aabb.org/Content/Members_Area/MembersAreaRegulatory/DonorSuitability/bpacdefernat030906.htm.
39. Kaiser Daily HIV/AIDS Report. 2008a. California County Board of Supervisors votes to oppose FDA policy barring MSM from donating blood. February 28. Available at http://www.kaisernetwork.org/dailyreports/repindex.cfm?hint=1&DRID=50653.
40. Kaiser Daily HIV/AIDS Report. 2008b. Rep. Farr requests that policy barring MSM from donating blood be re-evaluated. April 4. Available at http://www.kaisernetwork.org/dailyreports/repindex.cfm?hint=1&DRID=51345.
41. Kass, N. E. 2001. An ethics framework for public health. American Journal of Public Health 19(11): 1776-1782.
42. Kassing, D. W. 2008. President's message: Campus blood drives. January 22. Available at http://www.sjsu.edu/president/communications/archives/kassing/blooddrives/letter.html.
43. Kirp, D. 1999. The politics of blood: Hemophilia activism in the AIDS crisis. In Blood feuds: AIDS, blood, and the politics of medical disaster, ed. R. Bayer and E. A. Feldman, 293-321. New York: Oxford University Press.
44. Lambert, B. 1990. Now, no Haitians can donate blood. New York Times, March 14: A20.
45. Lorch, D. 1990. F.D.A. policy to limit blood is protested. New York Times, April 21: 25.
46. Malcolm, A., P. Aggleton, M. Bronfman, J. Galvao, P. Mane, and J. Verrall. 1998. HIV-related stigmatization and discrimination: Its forms and contexts. Critical Public Health 8(4): 347-370.
47. Maluwa, M., P. Aggleton, and R. Parker. 2002. HIV- and AIDS-related stigma, discrimination, and human rights: A critical overview. Health and Human Rights 6(1): 1-18.
48. Murray, T. H. 1991. The poisoned gift: AIDS and blood. In A disease of society: Cultural & institutional responses to AIDS, ed. D. Nelkin, D. P. Willis, and S. V. Parris, 216-240. Cambridge: Cambridge University Press.
49. Nelkin, D. 1989. Communicating technological risk: The social construction of risk perception. Annual Review of Public Health 10: 95-113.
50. Oppenheimer, G. M. 1988. In the eye of the storm: The epidemi-ological construction of AIDS. In AIDS: The burdens of history, ed.E. Fee and D. M. Fox, 267-300. Berkeley: University of California Press.
51. Pesavento, M., and K. Schmidt. 2005. Blood drive benefits from relaxed Red Cross travel restrictions. Tufts Daily, April 22: 4.
52. Reik, R. A., J. W. Burch, R. R. Vassallo, and L. Trainor. 2006. Unique donor-suitability issues. Vox Sanguinis 90: 255-264.
53. Resnik, S. 1999. Blood saga: Hemophilia, AIDS, and the survival of a community. Berkeley: University of California Press.
54. Soldan, K., and K. Sinka. 2003. Evaluation of the de-selection of men who have had sex with men from blood donation in England. Vox Sanguinis 84: 265-73.
55. Spartan Daily Editorial Board. 2008. FDA blood drive policy needs to be re-evaluated. March 11. Available at http://www.thespartandaily.com/news/2008/03/11.
56. Stern, P. C., and H. V. Fineberg, eds. 1996. Understanding risk: Informing decisions in a democratic society. Washington, DC: National Academy Press.
57. Stramer, S. L. 2007. Current risks of transfusion-transmitted agents: A review. Archives of Pathology & Laboratory Medicine 131: 702-707.
58. Sullivan, R. 1983. City takes Haitians off list of high risk groups. New York Times, July 29: B3.
59. Volberding, P. 2004. Letter to Lester Crawford, Acting Commissioner of the FDA, November 8. Available at http://docs.google.com/viewer?a=v&q=cache:b-XOiMJQc98J:urlwww.fda.gov/ohrms/dockets/dailys/04/nov04/112604/04D-0193-emc00292-01.pdf+volberding+November+8,+2004&hl=en&gl=us&pid=bl&srcid=ADGEESim6NRHFYwzOpEi5wRCiDG0VzdNSlq_Ks06_tOFei-w1Wrp2e42FOhwOGwjFtTlL8HkuKMgRvGHeQGJDpYAHUlrjMxLn37H2H5xZw3utme9IG7dica5RpmfshtdzsSqsw1KjJ&sig=AHIEtbRgBpmmWDxDXKchxnDRvIXt2WeHw.
60. von Eschenbach, A. C. 2006. Civil rights policy statement. November 30. Available at http://www.fda.gov/oc/eeo/civilmemo.html.
61. Young, I. M. 1990. Justice and the politics of difference. Princeton, NJ: Princeton University Press.
62. Young, R. M., and I. H. Meyer. 2005. The trouble with "MSM" and "WSW": Erasure of the sexual-minority person in public health discourse. American Journal of Public Health 95(7): 1144-1149.